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Platelets undergo several modifications
during storage that reduce their posttrans-
fusion survival and functionality. One im-
portant feature of these changes, which
are known as platelet storage lesion, is
the shedding of the surface glycoproteins
GPIb- and GPV. We recently demon-
strated that tumor necrosis factor- con-
verting enzyme (TACE/ADAM17) medi-
ates mitochondrial injury-induced shedding
of adhesion receptors and that TACE activ-
ity correlates with reduced posttransfusion
survival of these cells. We now confirm that
TACE mediates receptor shedding and clear-
ance of platelets stored for 16 hours at 37°C
or 22°C. We further demonstrate that both
storage and mitochondrial injury lead to the
phosphorylation of p38 mitogen-activated
kinase (MAPK) in platelets and that TACE-
mediated receptor shedding from mouse
and human platelets requires p38 MAP ki-
nase signaling. Protein kinase C, extracellu-
lar regulated-signal kinase MAPK, and
caspases were not involved in TACE activa-
tion. Both inhibition of p38 MAPK and inacti-
vation of TACE during platelet storage led to
a markedly improved posttransfusion recov-
ery and hemostatic function of platelets in
mice. p38 MAPK inhibitors had only minor
effects on the aggregation of fresh platelets
under static or flow conditions in vitro. In
summary, our data suggest that inhibition of
p38 MAPK or TACE during storage may
significantly improve the quality of stored
platelets. (Blood. 2010;115:1835-1842)
Introduction
Patients with a low platelet count or hyporeactive platelets are at
increased risk of spontaneous bleeding or hemorrhage after injury
or surgery. To maintain a normal hemostatic state, they may require
a transfusion of platelets. After collection and processing, human
platelets are stored in plasma for only 5 to 7 days at 22°C, mainly
because a longer storage period would dangerously increase the
risk of bacterial contamination. However, improved methods of
pathogen inactivation could make it possible to extend platelet
shelf life. During storage, platelets unfortunately undergo numer-
ous modifications that alter their functional integrity and structure.
These changes are summarized as platelet storage lesion (PSL) and
are strongly associated with a decrease in platelet posttransfusion
survival and function.1 The main characteristics of PSL are:
(1) shape change, (2) reduced activation in response to agonists,
such as adenosine diphosphate (ADP), thromboxane A2 (TxA2), or
epinephrine, (3) secretion of platelet granules, and (4) exposure of
phosphatidylserine on the outer leaflet of the plasma membrane
accompanied by blebbing of microparticles.2 Furthermore, the
surface expression of the glycoproteins GPIb- and GPV, subunits
of the von Willebrand factor (VWF) receptor complex, is altered
during long-term storage,3,4 mainly by metalloproteinase-mediated
proteolysis of their ectodomain. The major sheddase for GPIb-
and GPV is tumor necrosis factor- converting enzyme (TACE;
ADAM17),5,6 which is a type I metalloproteinase involved in the
shedding of several transmembrane proteins (cytokines, growth factors,
receptors, or adhesion molecules) and implicated in developmental and
inflammatory processes.7 As a result of TACE activation on platelets,
130-kDa (glycocalicin) and 80-kDa soluble fragments of GPIb- and
GPV, respectively, are released. GPIb- shedding was proposed as a
platelet clearance mechanism in a study of human platelets transfused in
rabbits where the surface levels of GPIb- correlated with the platelets’
overall clearance.8 Our own studies demonstrated that TACE mediates
cleavage of GPIb- from injured mouse platelets and that TACE activity
leads to a reduced posttransfusion recovery of these cells.5,9
The p38 mitogen-activated kinase (MAPK) belongs to a family of
serine-threonine kinases, which are activated by dual phosphorylation of
threonine and tyrosine residues separated by a single amino acid.
Human platelets possess 4 isoforms of p38 MAPK (, , , and ), but
the most abundant forms are p38 MAPK- and -. p38 MAPK-
(named p38 MAPK) was shown to be activated in response to several
agonists, including thrombin,10,11 TxA2,12 collagen,13ADP,14 and VWF,15
but its role in platelet function remains controversial. Importantly,
inhibition of p38 MAPK showed only minor effects on platelet
aggregation induced by threshold concentrations of agonists,12,16 and
this effect, at least in part, may be the result of cross-reactivity of p38
inhibitors with cyclo-oxygenases and thus impairment of TxA2 genera-
tion.17 Recently, p38 MAPK inhibition has been proposed and investi-
gated as a new strategy to treat inflammatory disorders, such as
atherosclerosis,18 rheumatoid arthritis, and septic shock.19 All of these
pathologies involve the production and/or the release of TNF-, the
prototypical substrate of TACE.
In the present study, we confirm that TACE mediates the
shedding of GPIb- and GPV from stored platelets, and we
demonstrate that TACE is activated via a p38 MAPK-dependent
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pathway. We also propose that p38 MAPK inhibition during
storage improves the posttransfusion recovery without affecting the
hemostatic function of platelets in vitro and in vivo.
Methods
Animals
C57BL/6J wild-type mice were purchased from The Jackson Laboratory.
TACE/Zn mutant mice (C57BL/6J/129Sv background)20 were kindly
provided by Jaques Peschon (Amgen, Seattle, WA). TACEZn/Zn and
TACE/ chimeric mice were generated by injecting fetal liver cells from
TACEZn/Zn and TACE/ sibling embryos at day 16.5 of development
into irradiated C57BL/6J recipient mice (12.5 Gy; 107 cells per mouse).
IL4R/GPIb-21 transgenic mice were kindly provided by Jerry Ware
(University of Arkansas for Medical Sciences, Little Rock, AR). All mice
were bred and housed in our facilities. The Animal Care and Use
Committee of the Immune Disease Institute approved experimental
procedures.
Reagents and antibodies
The following were purchased: enoxaparin (Aventis Pharmaceuticals
Products); heparin-coated microcapillaries (VWR Scientific); collagen
reagent Horm (Nycomed); prostaglandin I2, caspase-1 and -3 inhibitor
N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone (Z-VAD),
mouse thrombin, FeCl3, carbonyl cyanide m-chlorophenylhydrazone
(CCCP), and sodium pyruvate (all from Sigma-Aldrich); p38 MAPK
inhibitors SB203580 and SB202190, protein kinase C (PKC) inhibitor
Ro31-8220, the extracellular regulated-signal kinase (ERK) inhibitor
PD98059 (all from EMD Chemicals); ADP (Bio/Data Corporation); murine
PAR4 receptor-activating peptide H GYPGKF-NH2 (PAR4-AP; Advanced
ChemTech); annexin V-phycoerythrin and carboxyfluorescein succinimidyl
ester (CFSE; Invitrogen); monoclonal antibody directed against human
GPIb-, mouse P-selectin, and tetraspanin (CD9; all from BD Biosciences);
and monoclonal antibodies against murine GPIb-, GPV, GPVI, and GPIX
(emfret Analytics).
Platelet preparation
Mouse platelets. Mice were anesthetized with isoflurane (Abbott Labora-
tories). Blood was obtained by retro-orbital bleeding and was collected into
tubes containing 100 g/mL enoxaparin in phosphate-buffered saline.
Enoxaparin was used as an anticoagulant for mouse blood instead of
calcium-chelating agents, such as acid citrate dextrose or citrate because
mouse integrins require extracellular Ca2 concentrations of more than
100M for their activation.22 Platelet-rich plasma (PRP) was prepared by
centrifugation at 100g for 7 minutes. PRP and buffy coat were transferred
into new tubes and spun a second time at 100g for 5 minutes. PRP was
incubated with prostaglandin I2 (0.1 g/mL) at 37°C for 5 minutes. When
indicated, platelets were pelleted at 1000g for 3.5 minutes and washed in
modified Tyrode-N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
buffer (137mM NaCl, 0.3mM Na2HPO4, 2mM KCL, 12mM NaHCO3,
5mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid, 5mM glu-
cose, pH 7.4).
Human platelets. Human blood (9 volumes) from healthy volunteers
was collected in acid citrate dextrose (1 volume). All blood donors gave
written informed consent, and the research was approved by the Immune
Disease Institute’s Institutional Review Board in accordance with the
Declaration of Helsinki. Whole blood was centrifuged at 100g for
10 minutes, plasma and buffy coat were transferred to new tubes, and PRP
was obtained by centrifugation at 100g for 5 minutes.
In vitro platelet storage
PRP was treated as indicated in the respective figures and then stored at
37°C (or 22°C when indicated) under agitation for 16 hours for mouse PRP
and 72 hours for human PRP in Eppendorf tubes.
Flow cytometry
PRP or washed platelets were stained for 10 minutes with a saturating
amount of fluorophore-conjugated antibodies. After incubation, platelets
were immediately analyzed on a FACSCalibur flow cytometer (BD
Biosciences). Platelets were gated by their forward scatter/side scatter
FSC/SSC characteristics.
Immunoblot analysis
PRP or washed platelets were centrifuged at 1000g for 5 minutes. Cells
were lysed with radioimmunoprecipitation Assay buffer containing pro-
tease inhibitor cocktail Complete EDTA-free (Roche Diagnostics). Total
protein amount from the cell lysate and plasma was assayed according to
the specification of the BCA Protein Assay kit (Pierce Protein Research
Products; Thermo Fisher Scientific). A total of 30 g of proteins from
platelet lysates was used to immunoprecipitate the phosphorylated form of
p38 MAPK using a specific antibody immobilized on agarose hydrazide
beads (Cell Signaling Technology). Proteins were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a
polyvinylidene difluoride membrane. p38 MAPK was detected with a
monoclonal antibody against mouse total p38 MAPK (Cell Signaling
Technology) and a goat anti–rabbit-horseradish peroxidase coupled second-
ary antibody (Bio-Rad). Proteins were visualized by enhanced
chemiluminescence.
p38 MAPK activity
A p38 MAPK activity kit was obtained from Cell Signaling Technology.
Assays of p38 MAPK activity were performed exactly as directed by the
manufacturer using whole platelet lysates.
Aggregometry
PRP was diluted with modified Tyrode-N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid buffer containing 1mM CaCl2 in a prewarmed (37°C)
aggregometer cuvette to achieve a platelet concentration of 2 	 108/mL and
stirred. Agonists were added, and light transmission was recorded for
20 minutes on a 4-channel optical aggregation system (Chrono-log).
Flow chamber
Blood preparation. Mouse blood was drawn from the retro-orbital plexus into
heparinized tubes (30 U/mLlow molecular weight heparin, enoxaparin). Platelets
were labeled for 5 minutes with an Alexa488-labeled antibody against murine
GPIX (emfret Analytics). Human blood (9 volumes) was drawn into 3.8%
sodium citrate, and platelets were labeled with 1g/mL calcein for 10 minutes.
Perfusion. Whole blood, in the presence of 10M SB203580 or
vehicle (dimethyl sulfoxide [DMSO]), was perfused in a parallel-plate flow
chamber over glass slides coated with bovine type I collagen (200 g/mL;
Chrono-log) at a shear rate of 1200 seconds. Platelet adhesion was
visualized with a Nikon Ti-U inverted microscope (Nikon Instruments)
equipped with a Retiga EXL monochrome camera (QImaging). Images
were analyzed using Nikon NIS Elements software. The kinetics of
thrombus formation was evaluated by plotting the integrated fluorescence
intensity of all pixels in the image, regardless of their intensity, as a function
of time. The experiment was repeated 4 to 6 times for each condition.
Platelet transfusion and survival in mice
Platelets from mouse PRP were washed in modified Tyrode-N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer and labeled with
2 g/mL CFSE at 37°C for 30 minutes under agitation. A total of 108 plate-
lets/10 g of body weight was infused into the retro-orbital plexus of
C57BL/6J recipient mice (4-8 weeks old). The percentage of labeled
platelets was determined by flow cytometry in blood samples that were
collected at different time points after transfusion. The time point t 
 1 hour
was chosen as a readout for the rapid posttransfusion clearance of platelets,
whereas measurements at t 
 24 hours, 48 hours, 72 hours, and 96 hours
were used to determine the half-life of the transfused cells.
1836 CANAULT et al BLOOD, 4 MARCH 2010  VOLUME 115, NUMBER 9
For personal use only.on February 9, 2017. by guest  www.bloodjournal.orgFrom 
In vivo thrombosis model
Thrombus formation in vivo was studied as described previously.9 Briefly,
platelets were labeled for 10 minutes with calcein-green (1 g/mL) or
calcein-red/orange (1 g/mL) and infused into 3- to 5-week-old anesthe-
tized male mice. The mesentery was exposed through a midline abdominal
incision, and injury was induced by application of FeCl3. Vessels were
monitored until cessation of blood flow lasted longer than 30 seconds. It is
important to note that mice were injected with 5 	 107 SB203580-treated
stored platelets or 1.5 	 108 vehicle-treated stored platelets per 10 g of
body weight to achieve approximately 5% labeled platelets in circulation.
Platelet transfusion and tail bleeding time
Platelets were washed in modified Tyrode-N-2-hydroxyethylpiperazine-N-
2-ethanesulfonic acid, and 108 platelets/10 g of body weight was infused
into the retro-orbital plexus of IL4R/GPIb- transgenic recipient mice.
After 1 hour, the tail bleeding time was determined by removing 3 mm of
the distal mouse tail and immediately immersing the tail in 37°C phosphate-
buffered saline. A complete cessation of bleeding for more than 120 sec-
onds was defined as the bleeding time. Bleeding time measurements
exceeding 900 seconds were stopped by cauterization of the tail.
Statistics
Values are expressed as mean plus or minus SEM. The statistical
significance was assayed using the 1-way analysis of variance followed by
the Bonferroni multiple comparisons test or the 2-tailed unpaired Student
t test. A P value less than .05 was considered statistically significant.
Results
TACE activity mediates GPIb- shedding and affects the
posttransfusion recovery of in vitro stored platelets
One of the main characteristics of PSL is the down-regulation of
platelet surface receptors. TACE has been shown to be the major
enzyme responsible for shedding of GPIb- and GPV from
activated platelets,5,6 but its role in the proteolysis of these
glycoproteins in the setting of PSL has not been demonstrated. To
address whether TACE is activated during platelet storage, we
studied storage-induced changes in the expression levels of GPIb-
on the surface of wild-type mouse platelets and platelets expressing
inactive TACE (TACEZn/Zn). Our studies were carried out at 37°C
to accelerate the formation of PSL.1 We found that GPIb- was
markedly down-regulated from the surface of stored TACE/
platelets. In contrast, shedding was not significant in TACEZn/Zn
platelets (Figure 1A). Similar results were obtained when the
expression of GPV was measured (supplemental Figure 1A,
available on the Blood website; see the Supplemental Materials
link at the top of the online article), suggesting that storage-induced
TACE activation results in the cleavage of both GPIb- and GPV.
To test whether TACE activation during storage affects the
immediate posttransfusion recovery and/or the life span of trans-
fused platelets in circulation, we studied the survival of stored
TACEZn/Zn platelets and TACE/ platelets transfused into recipi-
ent mice. Compared with stored TACE/ platelets, stored TACEZn/Zn
platelets showed a significantly increased posttransfusion survival as we
observed approximately 60% more circulating TACEZn/Zn platelets at
t
 1 hour after infusion. In contrast, impaired TACE function did not
affect the life span of these cells in circulation (Figure 1B).
p38 MAPK controls the shedding of GPIb- and GPV during
storage
Several signaling pathways, including PKC, caspases, and various
members of the MAP kinase family, have been implicated in the
TACE-mediated shedding of membrane proteins.23-25 We used
pharmacologic inhibitors to assess the role of these pathways in the
release of GPIb- during platelet storage. Storage-induced shed-
ding of GPIb- was not affected by the broad range PKC inhibitor,
Ro 31-8220 (2 g/mL) or the ERK MAPK inhibitor, PD98059
(20M; Table 1). Furthermore, pretreatment of platelets with
Z-VAD (20M), a pan-caspase inhibitor, did not affect storage-
induced shedding of GPIb-, indicating that apoptosis is not
implicated in this process.
In contrast, storage-induced shedding of GPIb- (Figure 2A)
and GPV (supplemental Figure 1B) was prevented by the p38
MAPK inhibitor SB203580 (IC50  20M). Similar results were
observed with another p38 MAPK inhibitor, SB202190 (not
shown). Because p38 MAPK inhibitors are reported to block
COX-1 activity,17 we stored platelets in the presence of the COX
inhibitor acetylsalicylic acid (aspirin, 1mM). Aspirin did not
significantly inhibit the storage-induced shedding of GPIb- (not
shown), indicating that the effect of SB203580 and SB202190
resulted from a specific p38 MAPK inhibition. In blood banking
conditions, platelets are stored at 22°C to reduce the risk of
bacterial contamination and also because platelets seem to age
more slowly at 22°C compared with 37°C.1 Figure 2B shows that,
after 15 hours at 22°C, GPIb- was shed from the mouse platelet
Figure 1. TACEZn/Zn platelets are protected from storage-induced shedding of
GPIb- and increased posttransfusion clearance. (A) Surface expression of
GPIb- was determined by flow cytometry on freshly isolated or 15-hour stored
platelet-rich plasma (PRP) from TACE/ and TACEZn/Zn mice. Results are mean
 SEM; n 
 6. n.s. indicates not significant. (B) Platelets from stored PRP from
TACE/ and TACEZn/Zn mice were washed in Tyrode-N-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid buffer and labeled with CFSE. A total of 108 platelets/10 g of
body weight was infused intravenously into TACE/ mice. Blood was drawn at the
indicated time points, and platelets were immediately analyzed by flow cytometry.
Results are mean percentage CFSE-labeled platelets  SEM; n 
 4. ***P  .001.
*P  .05.
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surface, but to a lesser extent than if stored at 37°C. The presence of
SB203580 during storage at 22°C completely inhibited the shed-
ding of GPIb-. Similar results were obtained when the expression
of GPV was measured (supplemental Figure 1C).
Treating platelets with the cyanide derivative CCCP damages
the mitochondria and induces morphologic and functional changes
that resemble PSL.9 We investigated whether p38 MAPK plays a
role in TACE activation and platelet damage observed on CCCP
treatment. Washed platelets were incubated with CCCP (100M)
for 1 hour in the presence or absence of SB203580 or SB202190.
Both p38 MAPK inhibitors prevented the CCCP-induced shedding
of GPIb- (Figure 2C). Furthermore, SB203580 prevented storage-
induced changes in GPIb- expression on human platelets stored at
37°C for 72 hours (Figure 2D). This suggests that p38 MAPK
signaling is important for the development of PSL, both in murine
and human platelets.
Western blot analyses confirmed that phosphorylation of p38
MAPK was significantly increased in stored mouse platelets. As
expected, addition of SB203580 reduced the p38 MAPK phosphor-
ylation back to baseline (Figure 3A). Corroborating these results,
we could demonstrate phospho-p38 activity, measured by the
phosphorylation of an ATF-2 fusion protein, in lysates of stored but
not fresh platelets (Figure 3B). We also found that p38 MAPK was
rapidly (within 5 minutes) activated in CCCP-treated platelets, and
this activation increased over time (Figure 3C). Together, these
results suggest that the p38 MAPK pathway is the main intracellu-
lar signaling pathway involved in TACE activation in stored or
mitochondria-injured platelets.
Effect of p38 MAPK inhibition on platelet activation and
adhesion
Consistent with previous reports,2,8 stored platelets showed signs of
activation, including a small but significant increase in surface
expression of the -granule protein P-selectin, phosphatidylserine
exposure, and microparticle release (Table 2). The increase in
P-selectin expression was dependent on p38 MAPK signaling
(Table 2) but occurred in both TACE/ and TACEZn/Zn platelets
(not shown), suggesting that TACE is not important for this
process. Inhibition of p38 MAPK signaling prevented phosphatidyl-
serine exposure or microparticle formation only partially in the
stored platelets (Table 2), demonstrating that various signaling
pathways contribute to the development of PSL. Importantly,
murine platelets stored in the presence or absence of SB203580
showed a robust aggregation response to stimulation by PAR4-AP
or ADP (Figure 4A), suggesting that p38 MAPK inhibition does not
affect the hemostatic function of these cells. To confirm this
hypothesis, we also studied the effect of SB203580 on the adhesive
function of freshly isolated murine platelets. The presence of
SB203580 did not markedly reduce their aggregation in response to
Figure 2. p38 MAPK inhibition prevents the shedding
of GPIb- from stored mouse and human platelets.
GPIb- surface expression was assessed by flow cytom-
etry. (A) Wild-type mouse PRP was stored 1, 3, 6, 9, 12,
and 15 hours at 37°C in the presence of DMSO (vehicle)
or the p38 MAPK inhibitor SB203580 (40M); n 
 8.
***P  .001. (Inset) Western blot for GPIb- in lysates
from freshly isolated platelets and platelets stored for
16 hours in the presence or absence of SB203580. The
results are representative of 3 independent experiments.
(B) PRP was analyzed immediately (fresh) or after stor-
age at 22°C or 37°C in the presence of DMSO (vehicle)
or SB203580 (40M); n 
 10. (C) Washed platelets were
treated for 60 minutes at 37°C with DMSO (untreated) or
100M CCCP in the presence of DMSO (vehicle),
SB203580 (40M), or SB202190 (40M); n 
 9. (D) PRP
isolated from human blood was analyzed immediately
(fresh) or after 72 hours of storage at 37°C in the
presence of DMSO (vehicle) or SB203580 (40M); n 
 8.
Results are mean SEM. n.s. indicates not significant.
Table 1. Effect of pharmacologic inhibitors on GPIb- shedding
during platelet storage
Mouse platelets
GPIb-mean
fluorescence
( SEM)
P from
stored PRP
Fresh PRPr 421.9 ( 12.6)  0.001
Stored PRP (Vehicle) 34.1 ( 5.5)
Stored PRP/PKC inhibitor (Ro 31-8220
2 g/mL)
28.5 ( 10.9) n.s.
Stored PRP/ERK inhibitor (PD98059
20M)
28.2 ( 8.9) n.s.
Stored PRP/Caspases inhibitor (Z-VAD
20M)
38.7 ( 9.1) n.s.
Surface expression of GPIb was measured by flow cytometry on fresh platelets
or platelets stored in presence of inhibitors of PKC (Ro 31-8220), ERK mitogen-
activated protein kinase (PD98059), caspases (Z-VAD), or dimethyl sulfoxide
(Vehicle). Results are given as mean SEM, n 
 8.
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ADP, collagen, or PAR4-AP (Figure 4B). Platelet adhesion to a
collagen matrix under arterial blood flow conditions was compa-
rable in the presence or absence of SB203580 (Figure 4C). Similar
results were observed with freshly isolated human platelets. We
observed only a minor effect of p38 MAPK inhibition on fresh
human platelet aggregation at threshold concentration of agonists.
SB203580-treated human platelet adhesion and aggregation in
collagen-coated flow chambers were indistinguishable from ve-
hicle controls (supplemental Figure 2A-B).
p38 MAPK inhibition and platelet function in vivo
We next tested whether p38 MAPK inhibition during storage
affects the posttransfusion survival and hemostatic function of
platelets. Consistent with our studies on the survival of stored
TACEZn/Zn platelets (Figure 1), we found that inhibition of p38
MAPK signaling during platelet storage resulted in a significantly
increased posttransfusion recovery of these cells (Figure 5A). To
study the impact of p38 MAPK inhibition on the hemostatic
function of stored platelets in vivo, we performed intravital
microscopy studies in a model of arterial thrombosis.26 To compare
the adhesion of both platelet preparations in the same animal, mice
were infused with 0.5 	 108 SB203580/stored platelets labeled
with calcein-red/orange and 1.5 	 108 vehicle/stored platelets
labeled with calcein-green. This resulted in comparable numbers of
labeled circulating platelets. As shown in Figure 5B, platelets
stored in the presence of SB203580 showed a markedly improved
adhesion to the damaged vascular wall and a better incorporation
into the growing thrombus. In addition, p38 MAPK inhibition
during storage significantly improved the function of human
platelets when we studied their adhesion to a collagen-coated
surface under flow at arterial shear rate (supplemental Figure 2C).
We next tested the ability of transfused platelets to rescue
bleeding in mice engineered to lack the extracellular, ligand
binding domain of GPIb- (IL4R/GPIb-).21 These mice present
a severe bleeding phenotype despite having normal platelet size
and a platelet count of approximately 65% to 70% of wild-type
mice.21 A total of 200 million wild-type platelets that were freshly
isolated or stored in the presence or absence of SB203580 was
transfused into IL4R/GPIb- recipient mice, and their tail bleed-
ing times were determined 1 hour later (Figure 5C). Without
infusion of exogenous platelets, the bleeding time of IL4R/
GPIb- mice was 881 ( 18) seconds and exceeded 900 seconds
in 7 of 8 mice. The infusion of fresh but not stored platelets
significantly lowered the bleeding time in recipient mice. Impor-
tantly, transfusion with platelets stored in the presence of a p38
MAPK inhibitor significantly reduced the bleeding time of trans-
fused IL4R/GPIb-mice (532 120 seconds).
Discussion
In previous works, we established a mouse model for platelet
storage lesion,9 and we demonstrated that TACE activity is
responsible for the reduced posttransfusion recovery and hemo-
static function of these mitochondria-injured platelets in mice.5 In
the present study, we confirm that TACE is activated during platelet
storage, leading to a reduced posttransfusion recovery of these
cells. In an attempt to identify new means to improve platelet
storage conditions, we thus focused our attention on the mechan-
ism(s) regulating TACE activation in stored platelets. Surprisingly,
the PKC pathway, which has been considered the major signaling
pathway mediating TACE activation in platelets,5,6,27 was not
Figure 3. Phosphorylation and activity of p38 MAPK
are increased during in vitro storage of platelets.
Mouse platelets were isolated from fresh PRP or PRP
stored in the presence of SB203580 (40M) or DMSO
(vehicle), washed in Tyrode-N-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid buffer, and lysed immediately.
(A) Immunoprecipitated phospho-p38 MAPK was de-
tected by Western blot analysis using a specific antibody
for p38 MAPK and quantified (mean  SEM); n 
 4.
(B) The activity of phosphorylated p38 MAPK was as-
sessed in lysates from 2 different preparations of freshly
isolated or stored platelets by its ability to phosphorylate
the substrate fusion protein ATF-2. (C) Phosphorylation
of p38 and ATF-2 in platelets that were treated with
100M CCCP for the indicated times. Total p38 MAPK
was assessed in platelet lysates by Western blot analysis
using a specific antibody for p38 MAPK.
Table 2. Effect of storage with or without p38 MAPK inhibitor on platelet parameters
Fresh PRP Stored PRP (vehicle) Stored PRP/SB203580
P-selectin, mean ( SEM) 4.3 ( 0.1) 12.9 ( 2.2)** 6.3 ( 0.4)
GPIV, mean ( SEM) 20.3 ( 0.5) 17.6 ( 2.0) 19.0 ( 0.8)
CD9, mean ( SEM) 1133 ( 35.6) 1034 ( 123.8) 1024 ( 45.0)
Phosphatidylserine, mean ( SEM) 9.3 ( 0.3) 40.8 ( 7.9)*** 28.2 ( 3.8)*
Microparticles, mean ( SEM) 29.4 ( 2.9) 201.0 ( 16.5)*** 169.6 ( 12.0)***
Surface expressions of P-selectin, GPVI, CD9, phosphatidylserine and microparticle counts were determined by flow cytometry. Microparticles are defined as particles
smaller than platelets that are double positive for GPIX and GPIIb. Results are shown as mean SEM. Microparticles released per 1000 platelets, n 
 6.
MAPK indicates p38 mitogen-activated kinase; and PRP, platelet-rich plasma.
***Statistically different to Fresh PRP at p 0.001
**Statistically different to Fresh PRP at p 0.01
*Statistically different to Fresh PRP at p 0.05
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critical for TACE activation during platelet storage (Table 1).
Based on the effect of pharmacologic inhibitors, our studies
suggest that TACE-mediated receptor shedding in stored platelets
depends on signaling by p38 MAPK (Figures 2-3) but is indepen-
dent of ERK MAPK (Table 1). We cannot be entirely sure that
some of the effects of the p38 MAPK inhibition are not the result of
off-target effects, the classic reservation about the use of inhibitors.
Interestingly, our group recently noticed that TACE is also
activated through p38 MAPK in platelets stimulated with H2O2 or
serotonin.28,29 These results indicate that the p38 MAPK pathway
regulates TACE activity in platelets not only during storage but also
in response to other stresses and physiologic stimuli.
The molecular mechanisms of TACE activation by p38 MAPK
during platelet storage remain to be characterized. Downstream
targets of p38 MAPK, such as MAPKAP-K216 and heat shock
protein 27 (HSP27),30 have been detected in platelets. One possible
mechanism could be that MAPKAP-K2 directly activates TACE,
as was reported for cPLA2 when platelets are stimulated with
H2O2.31 Alternatively, p38 MAPK may directly phosphorylate
TACE and thereby modulate its activity. Such a direct effect on
TACE was shown in vitro for ERK MAPK.24 The dissociation of
GPIb-IX-V/calmodulin complexes was also shown to prime the
receptor for TACE-mediated proteolysis.6 Therefore, one could
consider that p38 MAPK activation leads to the dissociation of
calmodulin from GPIb-IX-V by as-yet-undefined mechanisms.
Interestingly, although platelet clearance was linked to the apopto-
tic pathway,32 our studies show that caspase inhibition does not
interfere with TACE activation (Table 1).
TACE is involved in the shedding of many plasma membrane
proteins.33 In platelets, TACE has been shown to regulate the
Figure 4. p38 MAPK inhibition does not affect integrin-
mediated aggregation and adhesion to collagen un-
der flow of freshly isolated and stored murine plate-
lets. (A) PRP stored in the presence of DMSO (vehicle)
or SB203580 (40M) was examined in standard aggre-
gometry after addition of 5M ADP or 1mM PAR4-AP.
(B) Freshly isolated murine PRP was activated with the
indicated agonists in the presence or absence of
SB203580. Results are representative of 3 separate
experiments. (C) Platelets in freshly isolated murine blood
were labeled by the addition of an Alexa488-labeled
antibody to GPIX. Whole blood, in the presence or
absence of SB203580, was perfused over collagen at a
shear rate of 1200 seconds. Adhesion and thrombus
formation of fluorescently labeled platelets were moni-
tored over time. (Left) Representative images. (Right)
Fluorescence intensity (platelet adhesion) measured over
time. Results are mean  SEM; n 
 6 (3 different blood
preparations).
Figure 5. Inhibition of p38 MAPK during storage improves the
posttransfusion recovery and hemostatic function of platelets.
(A) Platelets from fresh PRP or PRP stored in the presence of DMSO
(stored) or SB203580 (40M; stored/SB203580) were washed and
labeled with 2 g/mL CFSE. A total of 108 platelets/10 g of body
weight was infused intravenously into a wild-type mouse. At the
indicated time points, blood was drawn and analyzed by flow
cytometry. Results are mean percentage of labeled platelets  SEM;
n 
 6. (B) FeCl3-induced thrombosis was studied in mesenteric
arterioles of mice transfused with 0.5 	 108 SB203580/stored plate-
lets labeled with calcein-red/orange and 1.5 	 108 vehicle/stored
platelets labeled with calcein-green. Platelet adhesion (tethering) and
thrombus growth were monitored until complete vessel occlusion
occurred (occlusion). Representative images are shown. (C) IL4R/
GPIb--tg mice were transfused with the indicated platelet prepara-
tions (108 platelets/10 g of body weight). The tail bleeding time was
measured 1 hour after platelet transfusion. n.s. indicates not signifi-
cant.
1840 CANAULT et al BLOOD, 4 MARCH 2010  VOLUME 115, NUMBER 9
For personal use only.on February 9, 2017. by guest  www.bloodjournal.orgFrom 
surface expression of GPIb-, GPV, and semaphorin 4D.5,6,27 So
far, which substrate of TACE provides the survival or clearance
signal for transfused platelets has not been addressed. One poten-
tial candidate is GPIb-, the platelet receptor for von Willebrand
factor. GPIb- has also been implicated in the clearance of platelets
that were stored at 4°C. As shown by Hoffmeister et al,34
refrigeration of platelets for 1 hour followed by rewarming leads to
the clustering of GPIb- on the cell surface and clearance by Mac-1
(CD11b/18)–bearing hepatic macrophages, suggesting different
mechanisms of clearance for platelets stored at room temperature
or 4°C. Interestingly, however, prolonged refrigeration (48 hours)
before rewarming caused shedding of GPIb- and GPV, and
receptor shedding and the clearance of these cells were prevented
by adding metalloproteinase inhibitors during storage.35 Thus, the
clearance mechanisms of platelets stored at 4°C or room tempera-
ture for an extended period of time seem to be very similar. There
are several potential explanations for how GPIb- shedding may
cause platelet clearance. First, the cleavage of the GPIb- moiety
may expose a novel ligand (the clearance signal) on the GPIb-V-IX
complex. This signal could be clusters of the remaining truncated
subunits of the VWF receptor or a neoepitope on the truncated
receptor that was not accessible before. Alternatively, the clearance
signal may derive from the loss of repulsive negative charges
provided by the heavily O-glycosylated extracellular domain of
GPIb-. Further investigations are needed to identify the relevant
substrate(s) of TACE and the pathways of recognition of the
platelets after TACE activation during storage.
Our studies demonstrate that p38 MAPK plays a key role in the
generation of PSL and the clearance of stored platelets (Figure 5A).
Platelets stored in the presence of a p38 MAPK inhibitor showed a
markedly improved hemostatic function in vivo. Inhibition of p38
MAPK increased both the incorporation of stored platelets into a
growing thrombus in wild-type mice and the efficacy of these
platelets to arrest hemorrhaging in mice with a severe bleeding
phenotype (Figure 5B-C). It is well known that p38 MAPK
signaling regulates cellular functions other than receptor shedding.
Thus, infusion of platelet concentrates containing p38 inhibitors
may lead to unwanted side effects in patients. However, there are
advantages to the use of inhibitors in platelet concentrates that will
limit these complications. First, p38 MAPK inhibitors would be
used at optimal doses to inhibit PSL in platelet concentrates. On
transfusion into patients, the p38 MAPK inhibitor would be diluted
and its concentration in the circulation would be markedly lower. In
addition, although the inhibitor seems to be active over days in
stored platelets, its half-life in vivo should be much shorter because
of the rapid clearance of such compounds from the circulation.36
In conclusion, our data show that p38 MAPK signaling is not a
central component in platelet integrin activation and thus thrombus
formation. We suggest that inhibition of p38 MAPK signaling
during platelet storage may be a powerful means to improve the
efficacy of platelet transfusions. This conclusion is supported by
our findings that platelets stored in the presence of p38 MAPK
inhibitors (1) show a markedly improved posttransfusion survival
and (2) have a significantly improved hemostatic function on
infusion in mice.
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